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Abstract
Introduction Inflammatory breast cancer (IBC) is an aggressive
form of breast cancer associated with overexpression of Her2/
Neu (human epidermal growth factor-like receptor 2 (HER2))
and poor survival. We investigated survival differences for IBC
patient cases based on hormone receptor status and HER2
receptor status using data from the California Cancer Registry,
as contrasted with locally advanced breast cancer (LABC),
metastatic breast cancer (MBC) and non-T4 breast cancer.
Methods A case-only analysis of 80,099 incident female breast
cancer patient cases in the California Cancer Registry during
1999 to 2003 was performed, with follow-up through March
2007. Overall survival (OS) and breast cancer-specific survival
(BC-SS) were analyzed using Kaplan–Meier methods and Cox
proportional hazards ratios.
Results A total of 2,014 IBC, 1,268 LABC, 3,059 MBC, and
73,758 non-T4 breast cancer patient cases were identified.
HER2+  was associated with advanced tumor stage (P  <
0.0001). IBC patient cases were more likely to be HER2+ (40%)
and less likely to be hormone receptor-positive (HmR+) (59%)
compared with LABC (35% and 69%, respectively), MBC (35%
and 74%), and non-T4 patient cases (22% and 82%). HmR+
status was associated with improved OS and BC-SS for each
breast cancer subtype after adjustment for clinically relevant
factors. In multivariate analysis, HER2+ (versus HER2-) status
was associated with poor BC-SS for non-T4 patient cases
(hazards ratio = 1.16, 95% confidence interval 1.05 to 1.28)
and had a borderline significant association with improved BC-
SS for IBC (hazards ratio = 0.82, 95% confidence interval =
0.68 to 0.99).
Conclusions Despite an association with advanced tumor
stage, HER2+ status is not an independent adverse prognostic
factor for survival among IBC patient cases.
Introduction
Inflammatory breast cancer (IBC) is an aggressive disease
characterized biologically by dermal lymphatic invasion with
tumor emboli and angiogenesis, and characterized clinically by
breast tenderness and skin induration overlying the breast,
typically without underlying palpable mass [1]. IBC is a rapidly
progressive tumor, with propensity for metastatic tumor
spread, and poor overall survival (OS) compared with non-IBC
locally advanced breast cancer (LABC). Although relatively
rare (that is, 2% of all breast cancer patient cases), time-trend
BC-SS: breast cancer-specific survival; CCR: California Cancer Registry; CI: confidence interval; EOD: extent of disease; ER: estrogen receptor; 
HER2: human epidermal growth factor-like receptor 2; IBC: inflammatory breast cancer; LABC: locally advanced breast cancer; MBC: metastatic 
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data from the US National Cancer Institute Surveillance, Epi-
demiology, and End Results (SEER) database suggest that
the incidence of IBC may be increasing [2,3].
Despite multidisciplinary treatment with chemotherapy, radia-
tion and surgery, IBC still carries a poor prognosis, with a 5-
year survival rate of about 30% [4], with no significant change
in the prognosis over the past 30 years [5]. Advances in the
treatment of IBC have been hampered by a general lack of
prognostic or predictive parameters, in part because the rarity
of this tumor has made it difficult to conduct large clinical trials
[6]. Population-based analyses of SEER data reveal that IBC
has distinct epidemiologic differences from LABC and non-T4
breast cancer [2]. For example, IBC patient cases with estro-
gen receptor (ER)-negative tumors were shown to have
decreased breast cancer-specific survival (BC-SS) compared
with those with ER-positive tumors (2.0 years vs. 4.0 years). In
addition, several small studies have shown that a high propor-
tion of IBC tumors are positive for Her2/Neu (human epider-
mal growth factor-like receptor 2 (HER2)) receptor compared
with historic data for non-T4 patient cases [7-9]. HER2 is a
proto-oncogene located on chromosome 17. It is overex-
pressed in about 25% to 30% of breast cancer and in general
is associated with a more aggressive breast cancer phenotype
[10]. There has been interest in investigating the role of HER2
receptor status in IBC survival, but recording of HER2 recep-
tor status is not available in the SEER database. Previously
Caggiano and colleagues used data from the California Can-
cer Registry (CCR) to show that HER2 status did not differen-
tiate survival among ER-negative/progesterone receptor (PR)-
negative patient cases [11]. However, results for IBC were not
reported. One report indicates that HER2 receptor status is
not an independent risk factor for survival in ER-negative/PR-
negative invasive breast cancer in general [12]. Another report
shows that HER2 status does not significantly affect recur-
rence-free survival in both univariate and multivariate models
among 179 IBC patients [13]. Thus far, however, the useful-
ness of HER2 receptor status as a prognostic factor for sur-
vival among IBC patient cases in a population-based setting is
still unclear.
In the present study, we use data from the CCR to estimate
differences in OS for IBC, LABC, metastatic breast cancer
(MBC) and non-T4 breast cancer based on hormone and
HER2 receptor status. In doing so, our goal is to evaluate
these potential prognostic factors for survival after diagnosis
of IBC. We have restricted our analyses to a period prior to
2005, when trastuzumab became widely used in the adjuvant
setting for treatment of locoregional breast cancer [14,15].
Materials and methods
Study population
We performed a retrospective, case-only analysis of 80,099
incident female breast cancer patient cases in CCR during
1999 to 2003 with follow-up through March 2007. The CCR
is part of the National Cancer Institute's SEER program, and is
the largest contiguous-area, population-based cancer registry
in the world [16]; standardized data collection and quality con-
trol procedures have been in place since 1988 [17-19]. Data
were abstracted from medical and laboratory records by
trained tumor registrars. The tumor site and histology were
coded according to World Health Organization criteria in the
International Classification of Diseases for Oncology [20].
Patient cases were extracted based on the SEER primary site
recode 26000 for breast cancer. IBC, LABC, and non-T4
breast cancer were identified using the extent of disease
(EOD) coding for tumor extension and tumor size in addition to
pathologic International Classification of Diseases ICD-O-3
coding, as has been done previously [2].
The SEER extent of disease and surgical staging variables
were used to derive tumor node metastasis (TNM) data.
Patient cases identified through death certificate or autopsy
only were excluded. Recorded data included clinical informa-
tion such as stage at presentation, histology, treatment during
the first course of therapy, and vital status. Socioeconomic
status (SES) is recorded as a single index variable in the CCR
using statewide measures of education, income, and occupa-
tion from census data, as described previously [21]. The SES
variable used is described in full elsewhere [22-24]. Quintiles
for the SES score were analyzed. Cause of death was
recorded according to International Classification of Diseases
criteria in effect at the time of death. The last date of follow-up
was either the date of death or the last date of contact.
Hormone-receptor and Her2/Neu status
We classified patient cases as hormone receptor-positive if
either the ER marker or the PR marker was positive, and as
hormone receptor-negative if both markers were negative.
Otherwise, patient cases were classified as hormone receptor
unknown. Neither assay type nor titer was available in the data-
set for either of these markers. HER2 status was classified as
positive or negative based on the coding in the CCR. The
method of detection for HER2 status (that is, fluorescent in
situ hybridization, immunohistochemistry) was not available.
Statistical analysis
Associations between categorical and dichotomous variables
were tested using Pearson's chi-squared test or Fisher's exact
test. Differences in continuous variables across more than two
groups were tested with the nonparametric Kruskall–Wallis
test. Survival estimates were generated with Kaplan–Meier
methods and compared with the log-rank test. Cox propor-
tional-hazards methods were used to compare OS and BC-
SS while adjusting for covariates. Covariates included in the
multivariate regression model included those factors known to
have prognostic value in breast cancer, including age (years),
ethnicity, tumor grade, SES quintile, treatment with surgery,
radiation therapy, and chemotherapy. All statistical analyses
were conducted using SAS 9.1 statistical software (SASAvailable online http://breast-cancer-research.com/content/11/1/R9
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Institute Inc., Cary, NC, USA). Statistical significance required
a two-tailed P value < 0.05.
Ethical considerations
The present study involved analysis of extant CCR data with
no subject intervention. No identities were linked to subject
records. This study was approved by the University of Califor-
nia Irvine Institutional Review Board under the category of
exempt status, and no consent form was required from the par-
ticipants (IRB#2006-5264).
Results
Demographic comparisons
Among the 80,099 incident patient cases identified in this
analysis were 2,014 IBC, 1,268 LABC, 3,059 MBC, and
73,758 non-T4 patient cases. Comparison of relevant clinico-
pathologic variables across the four major breast cancer cate-
gories analyzed is presented in Table 1. With a median age at
diagnosis of 57.3 years, IBC patient cases were younger in
age than LABC, MBC or non-T4 breast cancer patient cases.
A greater proportion of African Americans and Hispanics were
observed among IBC and LABC cases compared with non-T4
patient cases. A full 99% of non-T4 patient cases received sur-
gical treatment, compared with 75% for IBC cases, 83% for
LABC cases, and 44% for MBC cases. Treatment with radia-
tion therapy involved 49% of non-T4 and IBC patient cases,
39% for LABC patient cases, and 33% for MBC patient
cases. A greater proportion of IBC patient cases received
treatment with chemotherapy compared with LABC, MBC or
non-T4 patient cases. Non-T4 breast cancer patient cases
were more likely to be in the highest two SES quintiles than
were IBC, LABC, or MBC patient cases.
Breast tumor receptor status
Hormone receptor status was available for 84% of the study
cohort. Table 2 reveals the hormone receptor status by stage
at presentation for each of the investigated breast cancer cat-
egories. ER-positive and PR-positive status was highest
among non-T4 patient cases (80% ER, 68% PR), particularly
those with early-stage disease. Expression of ER and PR,
respectively, was lower among IBC patient cases (56%,
45%), LABC patient cases (67%, 54%) and MBC patient
cases (73%, 58%). A greater proportion of stage IV IBC
patient cases had ER-positive tumors compared with stage
IIIB patient cases (60% vs. 55%), but equal proportions had
PR-positive tumors (45% vs. 45%).
HER2 receptor status was available for 60% of the breast can-
cer patient cases in this study. Among those with data availa-
ble for HER2, IBC patient cases were noted to have a higher
proportion of HER2-positive patient cases (stage IIIB 40%,
stage IV 43%) compared with non-T4 patient cases (stage I,
18%; stage IIA, 23%; stage IIB, 28%; stage IIIA, 30%; stage
IIIB, 36%), LABC patient cases (35%) or MBC patient cases
(35%).
Cause of death and survival analysis by breast cancer 
subtype
Overall there were 13,991 deaths among the 80,099 patient
cases analyzed (17.5%). Cause of death was recorded as fol-
lows: breast cancer (5,963), heart disease (1,340), other
causes (2,593), and missing (4,109). Among those suffering
death in this study, breast cancer was responsible for 72% of
IBC deaths, 55% of LABC deaths, 73% of MBC deaths, and
31% of non-T4 deaths (P < 0.0001).
Univariate BC-SS analysis revealed significant differences in
survival across the major breast cancer categories (Figure 1).
Non-T4 patient cases (5-year BC-SS = 95%; median BC-SS
not reached (NR) at >95 months) had significantly improved
BC-SS compared with LABC patient cases (5-year BC-SS =
65%; median BC-SS NR at >95 months), IBC patient cases
(5-year BC-SS = 49%; median BC-SS = 57 months, 95%
confidence interval (CI) = 50 to 77), or MBC patient cases (5-
year BC-SS = 36%; BC-SS = 28 months, 95% CI = 27 to 31)
(P < 0.0001).
Survival analysis by breast tumor receptor status
Univariate and multivariate survival analyses using Cox propor-
tional hazards models for each of the four major breast cancer
subtypes by breast tumor receptor status are presented in
Tables 3 and 4. Hormone receptor-positive status (compared
with hormone receptor-negative status as a referent) was
associated with improved OS and BC-SS for IBC, LABC,
MBC, and non-T4 patient cases in univariate survival analysis,
and also after adjustment for age, race, grade, SES, surgery,
radiation therapy, and chemotherapy (Table 3). HER2+ status,
however, was not associated with OS for IBC, LABC, or MBC
patient cases in adjusted or unadjusted analyses (Table 4).
Non-T4 breast cancer patient cases were observed to have an
association with HER2+ status and poor OS on univariate
analysis (hazards ratio = 1.19 vs. HER2-, 95% CI = 1.12 to
1.27), which was borderline nonsignificant on multivariate
analysis. In multivariate analysis, HER2+ (versus HER2-) status
was associated with poor BC-SS for non-T4 patient cases
(hazards ratio = 1.16, 95% CI = 1.05 to 1.28), had no associ-
ation with BC-SS for LABC patient cases (hazards ratio =
0.96, 95% CI = 0.72 to 1.28) or MBC patient cases (hazards
ratio = 0.95, 95% CI = 0.82 to 1.11), and had a borderline sig-
nificant association with improved BC-SS for IBC patient
cases (hazards ratio = 0.82, 95% CI = 0.68 to 0.99) after
adjustment for age, race, grade, SES, surgery, radiation ther-
apy, and chemotherapy (Table 4).
Discussion
As expected, we observed that BC-SS is lower for IBC patient
cases compared with non-T4 and LABC patient cases (Figure
1). Similar to what we observed for LABC, MBC, and non-T4
breast cancer patient cases, hormone receptor-positive status
was associated with improved BC-SS and OS among IBCBreast Cancer Research    Vol 11 No 1    Zell et al.
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Table 1
Demographic characteristics for invasive breast cancer cases by each of the four investigated categoriesa
Inflammatory breast 
cancer (n = 2,014)
Locally advanced 
breast cancer (n = 
1,268)
Metastatic breast 
cancer (n = 3,059)
Non-T4 breast cancer 
(n = 73,758)
Total (n = 80,099)
Median (± SD) age at 
diagnosis (years)
57.3 ± 14.4 64.3 ± 16.3 61.9 ± 14.9 60.2 ± 13.8 60.2 ± 13.9
Race
Caucasian 1,252 (62%) 783 (62%) 2,009 (66%) 52,280 (71%) 56,324 (70%)
African-American 192 (10%) 126 (10%) 287 (9%) 4,008 (5%) 4,613 (6%)
Hispanic 412 (20%) 220 (17%) 503 (16%) 10,188 (14%) 11,323 (14%)
Asian 140 (7%) 122 (10%) 241 (8%) 6,808 (9%) 7,311 (9%)
Other 18 (0.9%) 17 (1%) 19 (0.6%) 474 (0.6%) 528 (0.7%)
Stage
I - - - 38,571 (52%) 38,571 (48%)
IIA - - - 21,308 (29%) 21,308 (27%)
IIB - - - 11,137 (15%) 11,137 (14%)
IIIA - - - 2,675 (4%) 2,675 (3%)
IIIB 1,520 (75%) 1,268 (100%) - 67 (<0.1%) 2,855 (4%)
IV 494 (25%) 0 (0%) 3,059 (100%) 0 (0%) 3,553 (4%)
Tumor grade
Grade 1 51 (3%) 82 (6%) 141 (5%) 16,458 (22%) 16,732 (21%)
Grade 2 433 (22%) 363 (29%) 764 (25%) 28,873 (39%) 30,433 (38%)
Grade 3 1,025 (51%) 616 (49%) 1,108 (36%) 21,466 (29%) 24,215 (38%)
Grade 4 95 (5%) 38 (3%) 81 (3%) 1,536 (2%) 1,750 (2%)
Unknown 410 (20%) 169 (13%) 965 (32%) 5,425 (7%) 6,969 (9%)
Estrogen receptor
Estrogen receptor-
positive
862 (56%) 653 (67%) 1,533 (73%) 49,960 (80%) 53,008 (79%)
Estrogen receptor-
negative
675 (44%) 319 (33%) 573 (27%) 12,419 (20%) 13,986 (21%)
Missing 477 296 953 11,379 13,105
Progesterone 
receptor
Progesterone 
receptor-positive
666 (45%) 511 (54%) 1,123 (58%) 40,555 (68%) 42,855 (67%)
Progesterone 
receptor-negative
819 (55%) 430 (46%) 826 (42%) 19,137 (32%) 21,212 (33%)
Missing 529 327 1,110 14,066 16,032
Hormone receptorb
Hormone receptor-
positive
916 (60%) 671 (69%) 1,578 (75%) 51,062 (82%) 54,227 (81%)
Hormone receptor-
negative
626 (40%) 303 (31%) 533 (25%) 11,499 (18%) 12,961 (19%)
Missing 472 294 948 11,197 12,911
HER2Available online http://breast-cancer-research.com/content/11/1/R9
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patient cases, even after adjustment for HER2 status and
other clinically relevant factors (Table 3). These findings are
generally in agreement with the prior study by Brown and col-
leagues showing that, in invasive breast cancer, hormone
receptor-negative status rather than HER2 status is a major
contributor to poor survival [12]. We observed that the propor-
tion of HER2-positive tumors is greater among IBC patient
cases (40% in stage IIIB and 43% in stage IV) than LABC,
MBC, or non-T4 patient cases. These findings are consistent
with previous studies worldwide estimating HER2 positivity at
36% to 50% of IBC patients [9,25]. This conserved rate of
HER2 positivity among IBC patient cases occurs even in areas
of the world with historically higher incidence of the disease,
such as Tunisia – where IBC accounts for approximately 6%
of all breast cancer (contrasted with 2.5% IBC in our study)
[26,27].
Despite reported observations that HER2 positivity occurs
more frequently in IBC, very few studies have specifically
examined whether HER2 receptor status was prognostic for
survival in IBC patients. Dawood and colleagues reported that,
in the absence of treatment with the HER2 receptor antibody
trastuzumab, there is no statistically significant difference in
recurrence-free survival observed between IBC patients with
HER2-positive breast cancer compared with HER2-negative
breast cancer [13]. Interestingly, after adjusting for patient and
tumor characteristics, patients with HER2-positive disease
had increased OS, presumably because most of them
received trastuzumab for their recurrent disease. Trastuzumab
may therefore play an important role in treatment of metastatic
or recurrent IBC. Sawaki and colleagues also did not find
HER2 positivity to be a significant prognostic factor in IBC;
however, their study was probably underpowered to detect
such a difference due to the small sample size (that is, an anal-
ysis of 46 patients within a single Japanese hospital) [9]. We
obtained similar results in the present study, involving a large
population-based database and sufficient statistical power to
detect small differences. We observed no statistically different
BC-SS characteristics for IBC patient cases based on HER2
receptor status at the time of diagnosis on unadjusted analy-
sis, and a borderline significantly improved survival for patient
cases with HER2+ tumors in the BC-SS adjusted analysis.
HER2-positive 477 (40%) 255 (35%) 506 (35%) 9,575 (22%) 10,813 (23%)
HER2-negative 703 (60%) 484 (65%) 942 (65%) 34,754 (78%) 36,883 (77%)
Missing 834 529 1,611 29,429 32,403
Surgical treatment
None 511 (25%) 218 (17%) 1,707 (56%) 612 (<1%) 3,048 (4%)
Mastectomy/
lumpectomy/other
1,500 (75%) 1,050 (83%) 1,352 (44%) 73,145 (99%) 77,047 (96%)
Unknown 3 (0.2%) 0 (0%) 0 (0%) 1 (0%) 4 (0%)
Radiation therapy
None 1,022 (51%) 779 (61%) 2,041 (67%) 37,334 (51%) 41,176 (51%)
Any 992 (49%) 489 (39%) 1,018 (33%) 36,422 (49%) 38,921 (49%)
Unknown 0 (0%) 0 (0%) 0 (0%) 2 (0%) 2 (0%)
Chemotherapy
None 351 (17%) 537 (42%) 1,345 (44%) 44,474 (60%) 46,707 (58%)
Any 1,625 (81%) 683 (54%) 1,606 (53%) 27,428 (37%) 31,342 (39%)
Unknown 38 (2%) 48 (4%) 108 (4%) 1,856 (3%) 2,050 (3%)
Socioeconomic status
Lowest 358 (18%) 235 (19%) 509 (17%) 7,786 (11%) 8,888 (11%)
Second lowest 379 (19%) 263 (21%) 584 (19%) 11,900 (16%) 13,126 (16%)
Middle 427 (21%) 265 (21%) 631 (21%) 15,376 (21%) 16,699 (21%)
High 465 (23%) 252 (20%) 705 (23%) 17,608 (24%) 19,030 (24%)
Highest 385 (19%) 253 (20%) 630 (21%) 21,088 (29%) 22,356 (28%)
aCalifornia Cancer Registry data, 1999 to 2004. P < 0.0001 for comparisons of each variable across the four major breast cancer subtypes. 
HER2, human epidermal growth factor-like receptor 2; SD, standard deviation. bHormone receptor-positive indicates estrogen receptor-positive 
and/or progesterone receptor-positive; hormone receptor-negative indicates estrogen receptor-negative and progesterone receptor-negative.
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Additionally, in the present analysis of data from the largest
geographically contiguous cancer registry in the world, we
found that HER2 is not prognostic for overall survival among
LABC or MBC patient cases, and that HER2-positive status is
associated with poor overall survival and BC-SS only among
non-T4 breast cancer patient cases.
There are several possible explanations for why HER2 is not
prognostic of decreased survival in IBC. IBC's aggressive dis-
ease characteristics may be unrelated to the presence of
HER2 receptor or the HER2 receptor tyrosine kinase activity.
Various theories have been proposed. For example, IBC
tumors are known to be highly angiogenic and angioinvasive,
with expression of proangiogenic factors that may contribute
to early metastatic disease [28,29], which therefore could be
related to poor survival. Increased expression of chemokine
receptors such as CCR7 [30] and genes that are related to
higher metabolic rates such as Ki-67 [31] may also contribute
Table 2
Hormone receptor and HER2 receptor status by stage at presentation for investigated breast cancer categoriesa
Inflammatory breast 
cancer
Locally 
advanced 
breast 
cancer
Metastatic 
breast 
cancer
Non-T4 breast cancer
Stage IIIB Stage IV Stage IIIB Stage IV Stage I Stage IIA Stage IIB Stage IIIA Stage IIIB
Estrogen 
receptor status
Estrogen 
receptor-
negative
536 (45%) 139 (40%) 319 (33%) 573 (27%) 4,836 
(15%)
4,323 
(24%)
2,510 
(26%)
730 (32%) 20 (36%)
Estrogen 
receptor-
positive
655 (55%) 207 (60%) 653 (67%) 1,533 
(73%)
27,491 
(85%)
13,778 
(76%)
7,091 
(74%)
1,565 
(68%)
35 (64%)
Number 
missing
329 148 296 953 6244 3,207 1,536 380 12
Progesterone 
receptor status
Progesterone 
receptor-
negative
640 (55%) 179 (55%) 430 (46%) 826 (42%) 8,482 
(28%)
6,166 
(35%)
3,495 
(38%)
973 (44%) 21 (41%)
Progesterone 
receptor-
positive
517 (45%) 149 (45%) 511 (54%) 1,123 
(58%)
22,326 
(72%)
11,222 
(65%)
5,748 
(62%)
1,229 
(56%)
30 (59%)
Number 
missing
363 166 327 1,110 7,763 3,920 1,894 473 16
Hormone 
receptor status
Hormone 
receptor-
negative
502 (42%) 124 (36%) 303 (31%) 533 (25%) 4,426 
(14%)
4,021 
(22%)
2,351 
(24%)
683 (30%) 18 (33%)
Hormone 
receptor-
positive
694 (58%) 222 (53%) 671 (69%) 1,578 
(75%)
28,003 
(86%)
14,138 
(78%)
7,267 
(76%)
1,617 
(70%)
37 (67%)
Number 
missing
324 148 294 948 6,142 3,149 1,519 375 12
HER2 receptor 
status
HER2-
negative
556 (60%) 147 (57%) 484 (65%) 942 (65%) 18,280 
(82%)
10,110 
(77%)
5,104 
(72%)
1,235 
(70%)
25 (64%)
HER2-
positive
367 (40%) 110 (43%) 255 (35%) 506 (35%) 4,058 
(18%)
2,953 
(23%)
2,010 
(28%)
540 (30%) 14 (36%)
Number 
missing
597 237 529 1,611 16,233 8,245 4,023 900 28
aCalifornia Cancer Registry data, 1999 to 2004. HER2, human epidermal growth factor-like receptor 2.Available online http://breast-cancer-research.com/content/11/1/R9
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adversely to survival. Numerous other molecules may contrib-
ute to IBC's aggressive behavior, including E-cadherin [32],
Rho proteins, and WISP3 [33,34]. Some of these molecules
may be responsible for micrometastatic disease early on and
thus increase IBC's tendency for recurrence [35]. Future stud-
ies may determine whether expression of these molecules is
prognostic of poor survival in IBC. Finally, it has been pro-
posed that an anthracycline-based chemotherapy regimen
may be more effective in HER2-positive tumors compared with
HER2-negative ones because HER2-positive tumors often
have higher expression of topoisomerase II, which is the target
for anthracyclines [13]. Selective killing of HER2 positive
tumor cells with anthracycline-based chemotherapy (with or
without anti-HER2 trastuzumab treatment) could therefore
possibly eliminate HER2 positivity's impact on recurrence-free
survival and OS.
Since HER2 receptor status is not prognostic for decreased
survival in IBC patients, it calls into question whether antibod-
ies directed to the HER2 receptor, such as Herceptin, may
improve survival in these patients. We were not able to per-
form this analysis in our study because data on specific chem-
otherapeutic agents utilized are not available in the CCR. As
described previously, in one relatively small study, trastuzumab
appeared to have improved survival in recurrent or metastatic
IBC, and HER2 positivity was associated with a trend towards
higher overall survival [13]. A strength of the study design is
that we restricted our analyses to the period prior to 2005,
when trastuzumab became widely used in the adjuvant setting
for treatment of locoregional breast cancer [14,15]; our analy-
ses should therefore not be confounded by this landmark
event.
Figure 1
Breast cancer-specific survival by breast cancer subtype Breast cancer-specific survival by breast cancer subtype. Survival in 
breast cancer patient cases diagnosed during 1999 to 2003 with fol-
low-up through March 2007, from the California Cancer Registry. IBC 
= inflammatory breast cancer; LABC = locally advanced breast cancer; 
MBC = metastatic breast cancer; non-T4, non-T4 breast cancer.
Table 3
Overall survival and breast cancer-specific survival for breast cancer cases by tumor hormone receptor statusa
Inflammatory breast cancer Locally advanced breast 
cancer
Metastatic breast cancer Non-T4 breast cancer
Positiveb Not positiveb Positive Not positive Positive Not positive Positive Not positive
Overall mortality
Number of events 427 494 185 306 432 1,069 2,330 5,789
Number at risk 626 916 303 671 533 1,578 11,499 51,062
Unadjusted HR 
(95% CI)
1 (ref) 0.62 (0.55 to 
0.71)
1 (ref) 0.56 (0.47 to 
0.68)
1 (ref) 0.60 (0.53 to 
0.67)
1 (ref) 0.52 (0.49 to 
0.54)
Adjusted HR 
(95% CI)c
1 (ref) 0.64 (0.56 to 
0.73)
1 (ref) 0.49 (0.40 to 
0.60)
1 (ref) 0.54 (0.48 to 
0.61)
1 (ref) 0.61 (0.58 to 
0.64)
Breast cancer-specific mortality
Number of events 338 318 138 129 340 739 1,239 1,313
Number at risk 626 916 303 671 533 1,578 11,499 51,062
Unadjusted HR 
(95% CI)
1 (ref) 0.52 (0.45 to 
0.61)
1 (ref) 0.33 (0.26 to 
0.42)
1 (ref) 0.54 (0.48 to 
1.62)
1 (ref) 0.22 (0.21 to 
0.24)
Adjusted HR 
(95% CI)c
1 (ref) 0.55 (0.47 to 
0.65)
1 (ref) 0.33 (0.25 to 
0.43)
1 (ref) 0.51 (0.44 to 
0.58)
1 (ref) 0.43 (0.39 to 
0.47)
aUnivariate and multivariate adjusted analysis of overall survival and breast cancer-specific survival. Data for cases with missing hormone receptor 
status suppressed from table. bData presented as number of cases: not positive, not hormone receptor-positive; positive, hormone receptor-
positive; ref, reference. cIncludes adjustment for age (years), ethnicity, grade, socioeconomic status quintile, treatment with surgery, radiation 
therapy, and chemotherapy. HR, hazards ratio; CI, confidence interval.Breast Cancer Research    Vol 11 No 1    Zell et al.
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Currently there are no specific treatment guidelines for IBC.
These IBC patients are often treated the same way as LABC
patient cases, with intensive adjuvant or neoadjuvant chemo-
therapy in addition to surgery and radiation therapy. Further tri-
als involving larger numbers of subjects with adequate power
are warranted to assess the efficacy of trastuzumab in HER2-
positive IBC. It is interesting that HER2 receptor status is not
an adverse prognostic factor for survival after diagnosis of
IBC, and yet trastuzumab may still benefit IBC patients, a find-
ing that warrants further research. It is noteworthy that the BC-
SS estimates for IBC noted in the CCR during the period
1999 to 2003 are higher than previous estimates in the SEER
during the period 1988 to 2000. Many factors could explain
this difference, as management strategies have evolved over
time. Optimal administration schedules of anthracyclines and
taxanes have been adopted in routine practice. For example,
dose-dense anthracycline-based chemotherapy [36,37], dose
intensification therapy [38], and metronomic (weekly) taxane
regimens [37,39,40] are associated with improved outcomes
in breast cancer. More recently, use of trastuzumab at time of
diagnosis has shown increased pathologic complete
response in HER2-positive IBC, and promising progression-
free survival has been reported with early follow-up [41,42]. In
as much as pathologic complete response is a surrogate of
prolonged survival in IBC, future population-based data after
2005 may reveal further HER2-positive survival improvements
among individuals with IBC.
There are several limitations to the present study. First, a large
proportion of the data were missing for ER (16%), PR (20%),
and HER2 (31%) tumor receptor status. All multivariate mod-
els were therefore analyzed with inclusion of patient cases
lacking tumor receptor status. The level of HER2 amplification
was not recorded in the cancer registry database. Additionally,
there are no available data on the specific chemotherapy
agents that patients received. It is unclear how many people
received trastuzumab, for example, or received other therapy
that might have affected survival. Only 81% of IBC patient
cases received chemotherapy, only 75% received surgery,
and 49% received radiotherapy. While these rates are low
compared with what one might expect from clinical trial data,
population-based data typically have lower proportions of
cases receiving treatment, as all patients are included in the
analysis (that is, even those with severe comorbid conditions
and poor performance status). Consistent with other popula-
tion-based research, there is also no information in the CCR
reporting performance status or comorbid conditions that
might influence survival. Finally, these population-based data
came from a wide variety of sources, and thus variation of ref-
erence values for tests of hormone receptor status probably
exists.
Conclusions
Our observations help characterize the relationship between
IBC, HER2 receptor status and the effects of HER2 status
effects on survival. Based on these observations, we conclude
Table 4
Overall survival and breast cancer-specific survival for breast cancer cases by tumor HER2 receptor statusa
Inflammatory breast cancer Locally advanced breast 
cancer
Metastatic breast cancer Non-T4 breast cancer
Positiveb Not positiveb Positive Not positive Positive Not positive Positive Not positive
Overall mortality
Number of events 400 280 239 131 648 347 4,128 1,397
Number at risk 703 477 484 255 942 506 34,754 9,575
Unadjusted HR 
(95% CI)
1 (ref) 0.99 (0.85 to 
1.15)
1 (ref) 1.01 (0.82 to 
1.26)
1 (ref) 0.99 (0.87 to 
1.12)
1 (ref) 1.19 (1.12 to 
1.27)
Adjusted HR (95% 
CI)c
1 (ref) 0.87 (0.75 to 
1.02)
1 (ref) 1.00 (0.81 to 
1.24)
1 (ref) 0.88 (0.77 to 
1.01)
1 (ref) 1.05 (0.99 to 
1.12)
Breast cancer-
specific mortality
Number of events 282 193 132 78 450 266 1,185 556
Number at risk 703 477 484 255 942 506 34,754 9,575
Unadjusted HR 
(95% CI)
1 (ref) 0.98 (0.81 to 
1.17)
1 (ref) 1.11 (0.84 to 
1.47)
1 (ref) 1.09 (0.94 to 
1.27)
1 (ref) 1.68 (1.52 to 
1.86)
Adjusted HR (95% 
CI)c
1 (ref) 0.82 (0.68 to 
0.99)
1 (ref) 0.96 (0.72 to 
1.28)
1 (ref) 0.95 (0.82 to 
1.11)
1 (ref) 1.16 (1.05 to 
1.28)
aUnivariate and multivariate adjusted analysis of overall survival and breast cancer-specific survival. Data for cases with missing hormone receptor 
status suppressed from table. bData presented as number of cases: not positive, not human epidermal growth factor-like receptor 2 (HER2)-
positive; positive, HER2-positive; ref, reference. cIncludes adjustment for age (years), ethnicity, grade, socioeconomic status quintile, treatment 
with surgery, radiation therapy, and chemotherapy. HR, hazards ratio; CI, confidence interval.Available online http://breast-cancer-research.com/content/11/1/R9
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that IBC's poor survival is probably unrelated to HER2 status.
Rather, the aggressive biological nature of IBC or other clinical
factors may explain the poor OS for IBC. Optimization of
chemotherapy schedules may have preferentially improved the
outcome of HER2-positive IBC in our study. Additional
improvements in HER2-positive survival could be attributed to
use of trastuzumab in the relapsed or metastatic setting. Fur-
ther survival improvements in HER2-positive IBC could be
expected with use of trastuzumab at diagnosis, widely imple-
mented in 2005. Validation of these findings from other popu-
lation-based studies is needed, in order to help characterize
the true prognostic and predictive factors for survival in IBC.
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